Reilly Financial Advisors LLC raised its holdings in Smith & Nephew plc (NYSE:SNN) by 3,938.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 43,092 shares of the medical equipment provider’s stock after acquiring an additional 42,025 shares during the period. Reilly Financial Advisors LLC’s holdings in Smith & Nephew were worth $1,876,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. First Trust Advisors LP purchased a new stake in shares of Smith & Nephew during the 4th quarter worth $201,000. Bank of New York Mellon Corp boosted its position in shares of Smith & Nephew by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 79,606 shares of the medical equipment provider’s stock worth $2,975,000 after purchasing an additional 3,422 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Smith & Nephew by 26.3% during the 4th quarter. Geode Capital Management LLC now owns 29,356 shares of the medical equipment provider’s stock worth $1,096,000 after purchasing an additional 6,110 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Smith & Nephew during the 4th quarter worth $206,000. Finally, MML Investors Services LLC boosted its position in shares of Smith & Nephew by 3.9% during the 4th quarter. MML Investors Services LLC now owns 14,377 shares of the medical equipment provider’s stock worth $537,000 after purchasing an additional 535 shares in the last quarter. 8.82% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have commented on SNN. Berenberg Bank restated a “hold” rating on shares of Close Brothers Group in a research report on Tuesday, July 23rd. Canaccord Genuity set a $23.00 target price on shares of Zymeworks and gave the stock a “buy” rating in a research report on Friday, May 3rd. Finally, Zacks Investment Research downgraded EXACT Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Smith & Nephew has a consensus rating of “Hold” and an average target price of $27.50.

Shares of NYSE:SNN traded up $0.77 during midday trading on Monday, hitting $45.23. 16,520 shares of the stock were exchanged, compared to its average volume of 437,438. The company has a market capitalization of $19.44 billion, a PE ratio of 22.36, a P/E/G ratio of 3.26 and a beta of 0.29. The company has a current ratio of 2.10, a quick ratio of 1.15 and a debt-to-equity ratio of 0.27. Smith & Nephew plc has a twelve month low of $32.22 and a twelve month high of $44.73. The firm has a 50 day simple moving average of $43.48.

Smith & Nephew Profile

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Further Reading: What is Call Option Volume?

Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN).

Institutional Ownership by Quarter for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.